文献速递癫痫

美国联邦医疗保险受益人伴或不伴癫痫对抗癫痫药与其他药物依从性的比较

Adherence to Antiseizure vs Other Medications Among US Medicare Beneficiaries With and Without Epilepsy.
PubMed 文献 · Neurology · 2022-01-24

这项回顾性队列研究利用美国联邦医疗保险数据,纳入83,819例癫痫受益人与20%无癫痫随机样本,比较2013至2015年抗癫痫药与非抗癫痫药按天数覆盖比例(PDC)衡量的依从性。癫痫患者中抗癫痫药依从性 adjusted 预测概率74%(95%CI 73%-74%),低于他汀类78%(95%CI 78%-79%)和左甲状腺素82%(95%CI 81%-82%);无癫痫者非抗癫痫药依从性77%(95%CI 77%-77%),低于癫痫患者的80%(95%CI 80%-81%)。约54%的用药依从性变异来自个体间差异。

要点

  • 癫痫患者中抗癫痫药与非抗癫痫药依从性中度相关(Spearman 0.44-0.50)。
  • 54%的用药依从性变异归因于个体间差异而非药物类别差异。
  • 癫痫患者非抗癫痫药依从性80%(95%CI 80%-81%),高于无癫痫者77%(95%CI 77%-77%)。

核心结论

  • 癫痫患者中抗癫痫药与非抗癫痫药依从性中度相关,约半数依从性变异源于个体间差异而非药物类别差异。
  • 调整后抗癫痫药依从性略低于数种非抗癫痫药,癫痫与非抗癫痫药依从性小幅升高相关。
  • 作者认为抗癫痫药不依从或可提示临床医生询问其他可能延长生命药物的依从性。

研究设计与样本

  • 回顾性队列研究,使用美国联邦医疗保险数据。
  • 纳入癫痫受益人(≥1种抗癫痫药且具有ICD-9-CM诊断编码)及20%无癫痫随机样本,共83,819例癫痫受益人。
  • 依从性以2013至2015年按天数覆盖比例(PDC)衡量,采用Spearman相关系数、Cohen κ统计量及多水平logistic回归分析。

主要发现

  • 抗癫痫药PDC与5种非抗癫痫药PDC的Spearman相关系数为0.44至0.50,Cohen κ为0.33至0.38。
  • 每对药物间个体内PDC差值均具统计学显著性(p < 0.01),但中位差值均非常接近0。
  • 54%的用药依从性变异来自个体间差异。
  • 调整后依从预测概率:抗癫痫药74%(95%CI 73%-74%),质子泵抑制剂74%(95%CI 74%-74%),抗高血压药77%(95%CI 77%-78%),选择性5-羟色胺再摄取抑制剂77%(95%CI 77%-78%),他汀类78%(95%CI 78%-79%),左甲状腺素82%(95%CI 81%-82%)。
  • 癫痫患者非抗癫痫药调整后依从预测概率80%(95%CI 80%-81%),无癫痫者为77%(95%CI 77%-77%)。

临床怎么用

  • 作者认为抗癫痫药不依从可能为临床医生提供重要线索,应询问患者对其他可能延长生命药物的依从性。
  • 作者认为改善依从性的干预措施除关注药物特异性行为外,也应重视患者个体层面的行为。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The objectives of this study were to compare adherence to antiseizure medications (ASMs) vs non-ASMs among individuals with epilepsy, to assess the degree to which variation in adherence is due to differences between individuals vs between medication classes among individuals with epilepsy, and to compare adherence in individuals with vs without epilepsy. METHODS: This was a retrospective cohort study using Medicare. We included beneficiaries with epilepsy (≥1 ASM, plus ICD-9-CM diagnostic codes) and a 20% random sample without epilepsy. Adherence for each medication class was measured by the proportion of days covered (PDC) in 2013 to 2015. We used Spearman correlation coefficients, Cohen κ statistics, and multilevel logistic regressions. RESULTS: There were 83,819 beneficiaries with epilepsy. Spearman correlation coefficients between ASM PDCs and each of the 5 non-ASM PDCs ranged from 0.44 to 0.50; Cohen κ ranged from 0.33 to 0.38; and within-person differences between the PDC of each ASM minus the PDC of each non-ASM were all statistically significant (p < 0.01), although median differences were all very close to 0. Fifty-four percent of variation in adherence across medications was due to differences between individuals. Adjusted predicted probabilities of adherence were as follows: ASMs 74% (95% confidence interval [CI] 73%-74%), proton pump inhibitors 74% (95% CI 74%-74%), antihypertensives 77% (95% CI 77%-78%), selective serotonin reuptake inhibitors 77% (95% CI 77%-78%), statins 78% (95% CI 78%-79%), and levothyroxine 82% (95% CI 81%-82%). Adjusted predicted probabilities of adherence to non-ASMs were 80% (95% CI 80%-81%) for beneficiaries with epilepsy vs 77% (95% CI 77%-77%) for beneficiaries without epilepsy. DISCUSSION: Among individuals with epilepsy, ASM adherence and non-ASM adherence were moderately correlated, half of the variation in adherence was due to between-person rather than between-medication differences, adjusted adherence was slightly lower for ASMs than several non-ASMs, and epilepsy was associated with a quite small increase in adherence to non-ASMs. Nonadherence to ASMs may provide an important cue to the clinician to inquire about adherence to other potentially life-prolonging medications as well. Although efforts should focus on improving ASM adherence, patient-level rather than purely medication-specific behaviors are also critical to consider when developing interventions to optimize adherence.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Terman SW, Kerr WT, Aubert CE, et al. Adherence to Antiseizure vs Other Medications Among US Medicare Beneficiaries With and Without Epilepsy. Neurology. 2022. PMID: 34893556. doi:10.1212/WNL.0000000000013119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。